What was the market valuation for Dravet syndrome in South Korea in 2024?

The market valuation for Dravet syndrome in South Korea was $14.75 Million in 2024. Read More

What is the projected market valuation for Dravet syndrome in South Korea by 2035?

The projected market valuation for Dravet syndrome in South Korea is $39.25 Million by 2035. Read More

What is the expected CAGR for the South Korea Dravet syndrome market during the forecast period 2025 - 2035?

The expected CAGR for the South Korea Dravet syndrome market during the forecast period 2025 - 2035 is 9.3%. Read More

Which companies are key players in the South Korea Dravet syndrome market?

Key players in the South Korea Dravet syndrome market include Biogen, GW Pharmaceuticals, Zogenix, Marinus Pharmaceuticals, Eisai, UCB, Novartis, and Sage Therapeutics. Read More

What are the main types of seizures associated with Dravet syndrome in South Korea?

The main types of seizures associated with Dravet syndrome in South Korea include myoclonic, atonic, partial, absence, tonic, and photosensitive seizures. Read More

What was the market value for seizure medications in the South Korea Dravet syndrome market in 2024?

The market value for seizure medications in the South Korea Dravet syndrome market was $8.5 Million in 2024. Read More

What is the projected market value for seizure medications by 2035?

The projected market value for seizure medications in the South Korea Dravet syndrome market is $22.5 Million by 2035. Read More

How much is expected to be spent on SCN1A testing in the South Korea Dravet syndrome market by 2035?

The expected expenditure on SCN1A testing in the South Korea Dravet syndrome market is projected to reach $15.0 Million by 2035. Read More

What is the market value for hospitals as end-users in the South Korea Dravet syndrome market in 2024?

The market value for hospitals as end-users in the South Korea Dravet syndrome market was $4.0 Million in 2024. Read More

What is the projected market value for hospitals as end-users by 2035?

The projected market value for hospitals as end-users in the South Korea Dravet syndrome market is $10.5 Million by 2035. Read More

South Korea Dravet Syndrome Market

South Korea Dravet Syndrome Market Research Report By Type of Seizures (Myoclonic seizures, Atonic seizures, Partial seizures, Absence seizures, Tonic seizures, Photosensitive seizures, Others), By Disease Diagnosis (Magnetic Resonance Imaging, Electroencephalography, SCN1A testing, Others), By Treatment Management (Seizure Medications, Ketogenic Diet, Vagus Nerve Stimulation, Others) and By End-User (Pharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic research institutes, Others) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

9.3%

2024 Market Size

$ 14.75 Million

2035 Market Size

$ 39.25 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/43534-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Type of Seizures (USD Million)
  1. 4.1.1 Myoclonic seizures
  2. 4.1.2 Atonic seizures
  3. 4.1.3 Partial seizures
  4. 4.1.4 Absence seizures
  5. 4.1.5 Tonic seizures
  6. 4.1.6 Photosensitive seizures
  7. 4.1.7 Others
2. 4.2 Medical Device, BY Treatment and Management (USD Million)
  1. 4.2.1 Seizure Medications
  2. 4.2.2 Ketogenic Diet
  3. 4.2.3 Vagus Nerve Stimulation
  4. 4.2.4 Others
3. 4.3 Medical Device, BY Diagnosis (USD Million)
  1. 4.3.1 Magnetic Resonance Imaging
  2. 4.3.2 Electroencephalography
  3. 4.3.3 SCN1A testing
  4. 4.3.4 Others
4. 4.4 Medical Device, BY End-user (USD Million)
  1. 4.4.1 Pharmaceutical Companies
  2. 4.4.2 Hospitals
  3. 4.4.3 Diagnostic Laboratories
  4. 4.4.4 Academic & research institutes
  5. 4.4.5 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Biogen (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 GW Pharmaceuticals (GB)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Zogenix (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Marinus Pharmaceuticals (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Eisai (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 UCB (BE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Novartis (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sage Therapeutics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SEIZURES
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TREATMENT AND MANAGEMENT
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY TYPE OF SEIZURES, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY TYPE OF SEIZURES, 2024 TO 2035 (USD Million)
14. 6.14 MEDICAL DEVICE, BY TREATMENT AND MANAGEMENT, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY TREATMENT AND MANAGEMENT, 2024 TO 2035 (USD Million)
16. 6.16 MEDICAL DEVICE, BY DIAGNOSIS, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
18. 6.18 MEDICAL DEVICE, BY END-USER, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF SEIZURES, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT AND MANAGEMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea South Korea Dravet Syndrome Market Segmentation

South Korea Dravet Syndrome Market By Type of Seizures (USD Million, 2025-2035)

Myoclonic seizures
Atonic seizures
Partial seizures
Absence seizures
Tonic seizures
Photosensitive seizures
Others

South Korea Dravet Syndrome Market By Treatment and Management (USD Million, 2025-2035)

Seizure Medications
Ketogenic Diet
Vagus Nerve Stimulation
Others

South Korea Dravet Syndrome Market By Diagnosis (USD Million, 2025-2035)

Magnetic Resonance Imaging
Electroencephalography
SCN1A testing
Others

South Korea Dravet Syndrome Market By End-user (USD Million, 2025-2035)

Pharmaceutical Companies
Hospitals
Diagnostic Laboratories
Academic & research institutes
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”